Edition:
India

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

25.19EUR
17 Nov 2017
Change (% chg)

€-0.08 (-0.32%)
Prev Close
€25.27
Open
€25.22
Day's High
€25.48
Day's Low
€25.09
Volume
1,061,352
Avg. Vol
567,166
52-wk High
€27.73
52-wk Low
€16.48

Select another date:

Mon, Nov 6 2017

BRIEF-Grifols gets approval from US FDA for new product

* EARNS APPROVAL FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR NEW PRODUCT FIBRIN SEALANT (HUMAN) COMPOSED OF TWO PLASMA PROTEINS AND INDICATED FOR SURGICAL USE IN ADULTS ‍​ Source text for Eikon:

BRIEF-Grifols 9-month net profit up 6.3 pct at 431.8 mln euros YoY

* 9-MONTH NET PROFIT 431.8 MILLION EUROS VERSUS 406.1 MILLION EUROS YEAR AGO

BRIEF-Grifols approves interim dividend of 0.18 eur/shr

* APPROVES INTERIM DIVIDEND OF 0.18 EURO PER SHARE PAYABLE DECEMBER 5‍​ Source text for Eikon:

Spain's Grifols to remain in Catalonia for now: source

MADRID Spain's Grifols has no plans to leave Catalonia at the moment but, if the current situation changes in a way which could affect the company's business, the board will take appropriate steps, a company sources said on Monday.

Spain's Grifols to remain in Catalonia for now -source

MADRID, Oct 9 Spain's Grifols has no plans to leave Catalonia at the moment but, if the current situation changes in a way which could affect the company's business, the board will take appropriate steps, a company sources said on Monday. (Reporting by Emma Pinedo; Writing by Paul Day; Editing by Jesus Aguado)

BRIEF-Grifols gets FDA approval for Prolastin-C

* SAYS GETS APPROVAL FROM FDA (US FOOD AND DRUG ADMINISTRATION) FOR PROLASTIN-C LIQUID AS A REPLACEMENT THERAPY‍​ TO TREAT RARE GENETIC DISORDER

BRIEF-Grifols H1 EBITDA up 16.4 pct versus last year

* H1 NET PROFIT 277.9 MILLION EUROS VERSUS 264.4 MILLION EUROS YEAR AGO

BRIEF-Grifols reaches 90 pct stake in Kiro Grifols

* SAYS BUYS ADDITIONAL 40 PERCENT OF KIRO GRIFOLS SL FOR 12.8 MILLION EUROS‍​

BRIEF-Grifols buys 44 pct stake in GigaGen for $35 mln

* SAYS BUYS 43.96 PERCENT SHAREHOLDING IN GIGAGEN INC FOR $35 MILLION

BRIEF-Faes Farma closes purchase of Laboratorios Diafarm

* CLOSES PURCHASE OF LABORATORIOS DIAFARM FOR 70 MILLION EUROS

Select another date: